Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
12.52
+0.08 (0.64%)
At close: Jun 17, 2026, 4:00 PM EDT
12.72
+0.20 (1.60%)
After-hours: Jun 17, 2026, 5:19 PM EDT
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $292.14 million as of June 17, 2026. Its market cap has increased by 146.92% in one year.
Market Cap
292.14M
Enterprise Value
79.32M
1-Year Change
146.92%
Ranking
Category
Stock Price
$12.52
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $292.14M, a decrease of -92.92%. That is a compound annual growth rate of -41.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 17, 2026 | 292.14M | -55.32% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vanda Pharmaceuticals | 349.99M |
| Enanta Pharmaceuticals | 343.85M |
| Opus Genetics | 334.54M |
| OmniAb | 331.99M |
| Upstream Bio | 331.42M |
| Silence Therapeutics | 324.97M |
| Lineage Cell Therapeutics | 319.10M |
| Abeona Therapeutics | 318.03M |